Active substance
Phenoxybenzamine
- US FDA 7
- UK MHRA 2
- NHS prices 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PHENOXYBENZAMINE HYDROCHLORIDE | 10MG | capsule · oral | PH HEALTH | Prescription | 24 Jan 2017 |
| PHENOXYBENZAMINE HYDROCHLORIDE | 10MG | capsule · oral | AMNEAL | Prescription | 27 Oct 2020 |
| PHENOXYBENZAMINE HYDROCHLORIDE | 10MG | capsule · oral | NOVITIUM PHARMA | Prescription | 19 Jul 2022 |
| PHENOXYBENZAMINE HYDROCHLORIDE | 10MG | capsule · oral | AUROBINDO PHARMA | Prescription | 8 May 2023 |
| PHENOXYBENZAMINE HYDROCHLORIDE | 10MG | capsule · oral | RISING | Prescription | 20 Jun 2023 |
| DIBENZYLINE | 10MG | capsule · oral | ADVANZ PHARMA | Discontinued | 26 Jan 1953 |
| PHENOXYBENZAMINE HYDROCHLORIDE | 10MG | capsule · oral | HIKMA PHARMS | Discontinued | 16 Jul 2012 |
UK MHRA United Kingdom — marketing authorisations
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| DIBENYLINE 10MG CAPSULES | PL 12762/0224 | MERCURY PHARMACEUTICALS LIMITED | POM |
| PHENOXYBENZAMINE 10MG CAPSULES | PL 12762/0224 | MERCURY PHARMACEUTICALS LIMITED | POM |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Phenoxybenzamine 10mg capsules | £129.21 | 30 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.